Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Case report describes obinutuzumab achieving renal remission in elderly podocytopathy with B-cell disorder
A Cancer Drug Cleared a Man's Failing Kidneys — and Doctors Aren't Sure Why
This single case report details the use of obinutuzumab in a 76-year-old male with podocytopathy and a suspected B-cell lymphoproliferative …
A blood cancer drug put a 76-year-old man's failing kidneys into complete remission within one month, offering hope for elderly patients wit…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates.
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome. Both patients showed clinic…
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…